Mankind Pharma Limited — Q1FY27 earnings call summary

Filed 04 August 2026 · Official transcript

Net debt reduced to INR3,377 Cr; net debt/EBITDA at 0.9x; capex at 4.9% of revenue
Domestic revenue ex-Consumer Healthcare up 11% y-y; chronic share rose to 40%, targeting 50% medium term
Management cautious on GLP-1 launch due to hypercompetition and price war; focusing on therapy approach
Consumer Healthcare growth soft at 3.8% due to cash and carry business discontinuation; expecting high single-digit to double-digit growth from Q2
Q1FY27 revenue increased 13% y-y to INR4,031 Cr; EBITDA margin improved 250 bps to 26.3%
Gross margin expanded 230 bps y-y to 72.8%; EBITDA margin gain driven by margin expansion and operating leverage
Chronic portfolio grew 15.8% y-y; acute portfolio recovered to 10.9% growth
International business grew 29% y-y; BSV segment grew 21% with domestic at 17% and international at 25%